Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)

1.18
Delayed Data
As of 1:55pm ET
 -0.05 / -4.08%
Today’s Change
1.10
Today|||52-Week Range
7.94
-72.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$39.4M

Company Description

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which focuses on the treatment of spinal cord injuries. Its treatment approach is the Neuro-Spinal Scaffold implant, which is designed for implantation at the site of injury within a spinal cord and is intended to treat acute SCI. The company was founded by Joseph P. Vacanti, Frank M. Reynolds and Robert Langer on November 28, 2005 and is headquartered in Cambridge, MA.

Contact Information

Invivo Therapeutics Holdings Corp.
One Kendall Square
Cambridge Massachusetts 02139
P:(617) 863-5500
Investor Relations:

Employees

Shareholders

Mutual fund holders6.09%
Other institutional12.44%
Individual stakeholders0.77%

Top Executives

Mark D. PerrinChairman & Chief Executive Officer
William D'AgostinoSenior Vice President-Operations
Christopher McNultyChief Financial & Accounting Officer
Thomas R. UlichChief Scientific Officer
Richard ToselliChief Medical Officer